Taeko Yamamoto is a seasoned corporate lawyer with extensive experience in complex transactions, including cross-border M&A, divestitures and joint ventures, representing domestic and international clients. Her practice includes advising start-up and emerging companies across numerous industries on formation, financing, corporate governance and business operational matters. In addition, she works with both emerging and established companies in the pharmaceutical and biotechnology industries on a broad range of commercial matters, including licensing agreements, research and development agreements, collaboration agreements and intellectual property protection.
Taeko’s experience also includes bank financing and secured transactions, including acquisition financings, bankruptcy liquidations, debtor-in-possession financings, equipment financing and leases, letters of credit and other UCC-related matters.
Her practice includes:
- Entity Selection
- Joint Ventures
- Mergers and Acquisitions
- Outside General Counsel/General Corporate/Business Advice
- Start-up and Emerging Companies
- Venture Capital Financing
- Partnership and LLC Operating Agreements
- Commercial Contracts
- Bank Financing and Secured Transactions
PRIOR WORK EXPERIENCE:
- Morrison & Foerster LLP
- Bingham McCutchen LLP
- Representation of an emerging biotechnology company in Series B, C, D, E and F rounds of financing.
- Representation of a pharmaceutical company in the purchase of minority equity interests in various start-up and emerging biotechnology companies, with investment amounts ranging from $500,000 to $2,000,000.
- Representation of a data strategy company in entity selection and formation issues.
- Representation of an educational software developer in entity selection, formation and operational issues in establishing and running a US subsidiary.
- Representation of the pharmaceutical division of a publicly-traded company in its $44 million purchase of a biotechnology collaboration partner.
- Representation of both lenders and borrowers in connection with syndicated and other secured loan transactions, in amounts ranging from several hundred thousand U.S. dollars to close to one billion U.S. dollars.